杜氏肌营养不良症治疗研究进展

Abstract
Figure/Table
References (29)
Related Citation (12)

Download: PDF (550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Duchenne muscular dystrophy (DMD) is a kind of X-linked recessive hereditary disease caused by mutations of the dystrophin gene. There is no effective therapy method at present. In recent years, with the increasing knowledge of the mechanisms and pathologic process of the disease, researchers have conducted studies of DMD therapy method and the effectiveness. These studies include developing pharmaceutical therapies for reducing inflammation, regulating calcium levels, promoting muscle growth and anti-fibrosis, developing auxiliary equipment to train or improve the life quality of patients, developing gene therapy strategies for DMD gene replacement, exon-skipping and gene editing, and investigating stem cell therapy. This paper summarizes the latest progress of each therapy for DMD.

Key words： Duchenne muscular dystrophy Pharmaceutical therapy Gene therapy Stem cell therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Yixian1 LI Changsheng1 WANG Beilei1 DANG Suying2

Cite this article:

YANG Yixian1 LI Changsheng1 WANG Beilei1 DANG Suying2. Research progress of therapies of Duchenne muscular dystrophy[J]. 中国医药导报, 2019, 16(31): 56-59.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I31/56

[1] Traynor K. Deflazacort approved for Duchenne muscular dystrophy [J]. Am J Health Syst Pharm，2017，74（6）：368.
[2] Hoffman EP，Riddle V，Siegler MA，et al. Phase 1 trial of vamorolone，a first-in-class steroid，shows improvements in side effects via biomarkers bridged to clinical outcomes [J]. Steroids，2018，134：43-52.
[3] Abou-Samra M，Boursereau R，Noel L，et al. Potential therapeutic action of adiponectin in Duchenne muscular dystrophy [J]. Neuromuscul Disord，2016，26：S129.
[4] Finkel R，Vandenborne K，Sweeney H，et al. MoveDMD：phase 2 trial of edasalonexent，an NF-κB inhibitor，in 4 to 7-year old patients with Duchenne muscular dystrophy [J]. Neuromuscul Disord，2017，27：S215.
[5] Markham BE，Kernodle S，Nemzek J，et al. Chronic dosing with membrane sealant poloxamer 188 nf improves respiratory dysfunction in dystrophic mdx and mdx/utrophin-/-mice [J]. PLoS One，2015，10（8）：e0134832.
[6] Maurício AF，de Carvalho SC，Santo Neto H，et al. Effects of dietary omega-3 on dystrophic cardiac and diaphragm muscles as evaluated by 1H magnetic resonance spectro-scopy：metabolic profile and calcium-related proteins [J]. Clin Nutr Espen，2017，20：60-67.
[7] Bush E，Ward C，Suchyna T，et al. AT-300，a calcium modulator，improves muscle force production and decreases muscle degeneration in D2-mdx model of Duchenne muscular dystrophy [J]. Neuromuscul Disord，2017，27：S192.
[8] Kennedy TL，Swiderski K，Murphy KT，et al. BGP-15 improves aspects of the dystrophic pathology in mdx and dko mice with differing efficacies in heart and skeletal muscle [J]. Am J Pathol，2016，186（12）：3246-3260.
[9] Andre MS，Johnson M，Bansal PN，et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent，domagrozumab（PF-06252616），increases muscle volume in cynomolgus monkeys [J]. Skelet Muscle，2017，7（1）：25.
[10] Bettica P，Petrini S，D′Oria V，et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy [J]. Neuromuscul Disord，2016，26（10）：643-649.
[11] Muntoni F，Maresh K，Davies K，et al. PhaseOut DMD：a Phase 2，proof of concept，clinical study of utrophin modulation with ezutromid [J]. Neuromuscul Disord，2017， 27：S217.
[12] Barzilai-Tutsch H，Bodanovsky A，Maimon H，et al. Halofuginone promotes satellite cell activation and survival in muscular dystrophies [J]. Biochim Biophys Acta，2016， 1862（1）：1-11.
[13] Pi?觡ol-Jurado P，Suárez-Calvet X，Fernández-Simón E，et al. Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy [J]. Cell Death Dis，2018，9（7）：776.
[14] McDonald CM，Campbell C，Torricelli RE，et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy（ACT DMD）：a multicentre，randomised，doubleblind，placebo-controlled，phase 3 trial [J]. Lancet，2017，390（10101）：1489-1498.
[15] Le Guiner C，Servais L，Montus M，et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy [J]. Nat Commun，2017， 8：16105.
[16] Kodippili K，Hakim CH，Pan X，et al. Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model [J]. Hum Gene Ther，2018，29（3）：299-311.
[17] Counsell JR，Asgarian Z，Meng J，et al. Lentiviral vectors can be used for full-length dystrophin gene therapy [J]. Sci Rep，2017，7（1）：79.
[18] Charleston JS，Schnell FJ，Dworzak J，et al. Eteplirsen treatment for Duchenne muscular dystrophy：Exon skipping and dystrophin production [J]. Neurology，2018，90（24）：e2146-e2154.
[19] Kinane TB，Mayer OH，Duda PW，et al. Long-term pulmonary function in Duchenne muscular dystrophy：comparison of eteplirsen-treated patients to natural history [J]. J Neuromuscul Dis，2018，5（1）：47-58.
[20] Passini MA，Gan L，Wood JA，et al. Development of PPMO for the treatment of Duchenne muscular dystrophy （P5.430）[J]. Neurology，2018，90（15 Supplement）.
[21] Panzara M，Zhang J，Rinaldi C，et al. Preclinical studies of WVE-210201，an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy （DMD） [J]. J Neurol Scie，2017，381：277-278.
[22] Muntoni F，Frank D，Sardone V，et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in patients with genetic mutations amenable to exon 53 skipping [J]. Neuromuscul Disord，2018，28：S5.
[23] Rodrigues M，Yokota T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases [M]. Methods Mol Biol，2018，1828：31-55.
[24] El Refaey M，Xu L，Gao Y，et al. In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice [J]. Circ Res，2017，121（8）：923-929.
[25] Amoasii L，Long C，Li H，et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy [J]. Sci Transl Med，2017，9（418）. pii： eaan8081.
[26] Lee K，Conboy M，Park HM，et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair [J]. Nat Biomed Eng，2017，1：889-901.
[27] Chakravarty T，Makkar RR，Ascheim DD，et al. ALLogeneic heart STem cells to achieve myocardial regeneration （ALLSTAR） trial：rationale and design [J]. Cell Transplant，2017，26（2）：205-214.
[28] Siemionow M，Cwykiel J，Heydemann A，et al. Dystrophin expressing chimeric （DEC） human cells provide a potential therapy for duchenne muscular dystrophy [J]. Stem Cell Rev，2018，14（3）：370-384.
[29] Benedetti S，Uno N，Hoshiya H，et al. Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy [J]. Embo Mol Med，2018，10（2）：254-275.